About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer

Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic natural killer (NK) cell therapies that are safe and accessible to cancer patients, today announced the appointment of Thorsten Graef, M.D., Ph.D., as Chief Medical Officer. As a highly respected drug development leader, Dr. Graef brings to Artiva more than a decade of experience building and managing clinical development organizations, global multidisciplinary groups and cross-functional teams.

“I am delighted to welcome Thorsten to our team. He brings substantive expertise to Artiva, including having led the development of IMBRUVICA® through its registration in a number of indications, coupled with his recent experiences in the NK cell therapy space,” stated Fred Aslan, MD, CEO of Artiva. “He joins Artiva as we transition from being a company with a single clinical trial to one with potentially multiple trials in both hematopoietic and solid tumor indications where we hope to demonstrate the clinical impact of allogeneic, off-the-shelf, NK cell therapies.”

“I was impressed by Artiva’s Manufacturing-First approach and pragmatic development program choices,” stated Dr. Graef. “NK cell therapies are making good clinical progress, but to achieve registration and commercial success, therapies will also need to be truly off-the-shelf and cost-effective with a scalable process in place. This is where I believe Artiva’s investments in manufacturing can strengthen and accelerate our development plans.”

Most recently, Dr. Graef served as Chief Medical Officer at Acepodia USA, with responsibility for all of the company’s research and clinical development activities. Prior to his role at Acepodia, he served as Vice President of Oncology Early Development at AbbVie Inc., overseeing clinical activities, including the development and regulatory preparations of 20+ clinical assets. In addition, he held a series of senior leadership roles, including Head of Global Clinical Development, at Pharmacyclics LLC before and after AbbVie Inc.’s acquisition of the company in May of 2015, where he led the development of IMBRUVICA (ibrutinib). Prior to Pharmacyclics, Dr. Graef served as medical director of Merck Research Lab, Oncology at Merck & Co., Inc.

Prior to his time in the life sciences industry, Dr. Graef was an attending physician in the hematology, oncology, and immunology department at the University Hospital of Düsseldorf in Germany. He received his M.D. in internal medicine and his Ph.D. in molecular medicines from Heinrich-Heine University Medical School in Düsseldorf and completed his postdoctoral research fellowship at the Stanford University School of Medicine. Dr. Graef has published more than 50 original peer-reviewed publications, including many in top journals, such as NEJM, Lancet, Blood, PNAS, and Journal of Experimental Medicine.

About Artiva Biotherapeutics

Artiva’s mission is to deliver highly effective, off-the-shelf, allogeneic NK cell-based therapies utilizing our Manufacturing-First approach, that are safe and accessible to cancer patients. Artiva’s pipeline includes AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. Artiva is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas. Artiva’s pipeline also includes AB-201, an anti-HER2 CAR-NK cell therapy candidate for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers, and AB-202, a CD19-specific CAR-NK cell therapy candidate for the treatment of B-cell malignancies. Artiva has entered into therapeutic NK cell collaborations with Merck Sharp & Dohme Corp. and with Affimed GmbH. Artiva’s AlloNK™ platform incorporates cell expansion, activation, and engineering technology developed by Artiva’s strategic partner, GC Cell Corporation, a member of the GC family of companies, a leading healthcare company in Korea. Artiva is headquartered in San Diego. For more information, visit www.artivabio.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.